Drug Trial Radar · NCT00376883
Pamidronate Prophylaxis in Multiple Myeloma 30 mg/Month Versus 90 mg/Month
Last checked: Nov 20, 2026Latest source record: Jan 4, 2007 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
500
Actual
Start
Jan 2000
Primary completion
Not stated
Study completion Oct 2006
Sponsor
- Lead sponsor
- Nordic Myeloma Study GroupAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Nordic Cancer Union
- First posted
- Sep 15, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Prevention
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Multiple myeloma is a malignant hematological disease dominated by monoclonal plasma cells in the bone marrow. Major symptoms are related to the bones due to an increased bone resorption and a decreased bone formation leading to bone pain and increased risk of fractures. The normal osteoclasts are responsible for bone degradation through stimulation from the malignant plasma cells. Bisphosphonates have been shown to inhibit the osteoclast activity but may have serious side-effects due to renal toxicity and the optimal dose have not been established. In a randomized double blinded design it is aim to compare the standard of monthly injections of 90 mg pamidronate with 30 mg. The primary end-point is physical function estimated by EORTC QLQ-C30 questionnaire at 12 months after starting the treatment in newly diagnosed treatment demanding multiple myeloma. Secondary end-points are skeletal related events, cost-utility analysis, response, response duration and survival and quality of life with respect to fatigue and pain.
Conditions
- Multiple Myeloma
Interventions
pamidronateDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Physical function at 12 months estimated by EORTC QLQ-C30 questionnaire
Locations
14 sites in 3 countries. Site status is shown where the registry gives one.
Department of Haematology B, Aalborg Hospital, University of Aarhus
Aalborg, Denmark
Hæmatologisk afd., Århus Universitetshospital
Aarhus, Denmark
Department of Haematology, Herlev University Hospital
Herlev, Denmark
Department of Hematology L, Rigshospitalet
København Ø, Denmark
Hematologisk seksjon, med avd, Haukeland Universitetssykehus
Bergen, Norway
Hematologisk avdeling Ullevål Sykehus
Oslo, Norway
Med avd B, Hematologisk seksjon, Universitetssykehuset Nord Norge
Tromsø, Norway
Hematologisk seksjon, St.Olav Hospital
Trondheim, Norway
Sahlgrenska Universitetsjukhuset Östra
Gothenburg, Sweden
Hematologkliniken, Universitetssjukhuset
Linköping, Sweden
Medicinklin, Universitetssjukhuset MAS,
Malmö, Sweden
Medicinkliniken, Universitetssjukhuset
Örebro, Sweden
Medicinklin, sekt för hematologi, Norrlands Universitetssjukhus
Umeå, Sweden
Medicinklinikken Akademiska sjukhuset
Uppsala, Sweden
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.